Numinus Wellness Inc.
NMNSF
Other OTC0.13
USD
- -
- -
Return %
Stock
S&P500
1Y
228.25
26.53
3Y
228.25
76.60
5Y
228.25
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Address
- Similar Companies
- Business
- Numinus Wellness Inc. (TSX: NUMI, OTCQX: NUMIF) operates as a mental healthcare company focused on advancing traditional and innovative behavioral health treatments, including evidence-based psychedelic-assisted therapies; it develops proprietary psychedelic-centered therapeutic products and services through laboratory and research and development processes, alongside clinical research management services for academic institutions and biotechnology firms, practitioner training programs such as psychedelic-assisted therapy training, and technology-driven clinic support solutions for efficiency and insurance reimbursement. The company conducts operations across clinical research via its Cedar Clinical Research unit, which manages multiple trials including selection for Cybin's Phase 3 CYB003 study for major depressive disorder; practitioner training with programs approved in states like Colorado; and the Numinus Network, emphasizing product development and operational data utilization post-clinic divestitures. Founded in 1964 and headquartered in Vancouver, British Columbia, Canada, Numinus targets patients and providers addressing depression, anxiety, PTSD, trauma, pain, and substance use disorders primarily in Canada and the United States. In late 2024, Numinus completed the sale of its five Utah wellness clinics to Stella MSO LLC for US$3.53 million, including a data-sharing partnership providing access to operational data from Stella's 12-clinic network to develop SaaS solutions for mental health clinic management; in February 2025, it initiated a strategic wind-down of non-operating subsidiaries such as Mindspace Services Inc., Neurology Centre of Toronto Inc., Numinus Bioscience Inc., Salvation Bioscience Inc., and Numinus Health Corp. to streamline its structure and enhance efficiency; leadership transitioned with Michael Tan appointed as CEO amid a shift to a leaner model prioritizing cash flow-positive operations and in-clinic psychedelic delivery support. Recent financial performance reflects this pivot, with fiscal Q3 2025 revenue rising 81.6% to $1.8 million, driven by 95.8% growth in clinical research to $1.6 million and gross margins expanding to 49.3% from 38.6%, alongside a 51.1% reduction in operating expenses.